{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=13",
    "query": {
      "intervention": "liposomal doxorubicin",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 1374,
    "total_pages": 138,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T22:19:40.157Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04506554",
      "title": "A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "AMVAC + Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2020-12-01",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-14T22:19:40.157Z",
      "location_count": 4,
      "location_summary": "Chapel Hill, North Carolina • Philadelphia, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04506554"
    },
    {
      "nct_id": "NCT00796120",
      "title": "An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Trabectedin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2008-11",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2015-12-10",
      "last_synced_at": "2026-10-14T22:19:40.157Z",
      "location_count": 6,
      "location_summary": "Santa Monica, California • Boston, Massachusetts • Albuquerque, New Mexico + 3 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00796120"
    },
    {
      "nct_id": "NCT00312208",
      "title": "Docetaxel in Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel,doxorubicin, cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 3299,
      "start_date": "2001-11",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2013-12-30",
      "last_synced_at": "2026-10-14T22:19:40.157Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00312208"
    },
    {
      "nct_id": "NCT00323323",
      "title": "CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "CHOP",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Plasma Samples",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2004-03",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-10-14T22:19:40.157Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323323"
    },
    {
      "nct_id": "NCT00005780",
      "title": "Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma",
        "Lymphoma, Mantle Cell"
      ],
      "interventions": [
        {
          "name": "EPOCH-R",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Idiotype vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2000-06-01",
      "completion_date": "2021-06-16",
      "has_results": true,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-14T22:19:40.157Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005780"
    },
    {
      "nct_id": "NCT00667342",
      "title": "A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteosarcoma",
        "Malignant Fibrous Histiocytoma (MFH) of Bone"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 43,
      "start_date": "2008-06-03",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2023-08-07",
      "last_synced_at": "2026-10-14T22:19:40.157Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Baltimore, Maryland • Bethesda, Maryland + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00667342"
    },
    {
      "nct_id": "NCT00307294",
      "title": "Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Thalidomide",
          "type": "DRUG"
        },
        {
          "name": "Doxil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2006-03",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2017-11-24",
      "last_synced_at": "2026-10-14T22:19:40.157Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00307294"
    },
    {
      "nct_id": "NCT02272790",
      "title": "Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "PLD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 95,
      "start_date": "2015-01-30",
      "completion_date": "2023-03-08",
      "has_results": true,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-10-14T22:19:40.157Z",
      "location_count": 18,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02272790"
    },
    {
      "nct_id": "NCT01055314",
      "title": "Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Rhabdomyosarcoma",
        "Childhood Alveolar Rhabdomyosarcoma",
        "Childhood Embryonal Rhabdomyosarcoma",
        "Metastatic Childhood Soft Tissue Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Untreated Childhood Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dactinomycin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate Liposome",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "Up to 49 Years"
      },
      "enrollment_count": 175,
      "start_date": "2010-01",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-29",
      "last_synced_at": "2026-10-14T22:19:40.157Z",
      "location_count": 121,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01055314"
    },
    {
      "nct_id": "NCT00217425",
      "title": "Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2006-09-14",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-10-14T22:19:40.157Z",
      "location_count": 110,
      "location_summary": "Greenbrae, California • Palo Alto, California • Fort Collins, Colorado + 77 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Illinois"
        },
        {
          "city": "Bloomington",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217425"
    }
  ]
}